Skip to main navigation Skip to search Skip to main content

Drug composition matters: The influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP

  • R. Lange
  • , J. M H de Klerk
  • , H. J. Bloemendal
  • , R. M. Ramakers
  • , F. J. Beekman
  • , M. M L van der Westerlaken
  • , N. H. Hendrikse
  • , R. ter Heine*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Introduction: 188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for treatment of osteoblastic bone metastases. It is known that the presence of carrier (non-radioactive rhenium as ammonium perrhenate) in the reaction mixture during labeling is a prerequisite for adequate bone affinity, but little is known about the optimal carrier concentration. Methods: We investigated the influence of carrier concentration in the formulation on the radiochemical purity, in-vitro hydroxyapatite affinity and the in-vivo bone accumulation of 188Rhenium-HEDP in mice. Results: The carrier concentration influenced hydroxyapatite binding in-vitro as well as bone accumulation in-vivo. Variation in hydroxyapatite binding with various carrier concentrations seemed to be mainly driven by variation in radiochemical purity. The in-vivo bone accumulation appeared to be more complex: satisfactory radiochemical purity and hydroxyapatite affinity did not necessarily predict acceptable bio-distribution of 188Rhenium-HEDP. Conclusions: For development of new bisphosphonate-based radiopharmaceuticals for clinical use, human administration should not be performed without previous animal bio-distribution experiments. Furthermore, our clinical formulation of 188Rhenium-HEDP, containing 10μmol carrier, showed excellent bone accumulation that was comparable to other bisphosphonate-based radiopharmaceuticals, with no apparent uptake in other organs. Advances in knowledge: Radiochemical purity and in-vitro hydroxyapatite binding are not necessarily predictive of bone accumulation of 188Rhenium-HEDP in-vivo. Implications for patient care: The formulation for 188Rhenium-HEDP as developed by us for clinical use exhibits excellent bone uptake and variation in carrier concentration during preparation of this radiopharmaceutical should be avoided.

Original languageEnglish
Pages (from-to)465-469
Number of pages5
JournalNuclear medicine and biology
Volume42
Issue number5
DOIs
Publication statusPublished - 1 May 2015
Externally publishedYes

Keywords

  • Bone affinity
  • Hydroxyapatite
  • Rhenium-188
  • Rhenium-188-HEDP
  • Rhenium-HEDP

Fingerprint

Dive into the research topics of 'Drug composition matters: The influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP'. Together they form a unique fingerprint.

Cite this